Fasimec Duo 50 mg/ml + 1 mg/ml oral suspension for sheep

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Triclabendazole; Ivermectin

から入手可能:

Elanco GmbH

ATCコード:

QP54AA51

INN（国際名）:

Triclabendazole; Ivermectin

投薬量:

50, 1 milligram(s)/millilitre

医薬品形態:

Oral suspension

処方タイプ:

POM: Prescription Only Medicine as defined in relevant national legislation

治療領域:

ivermectin, combinations

認証ステータス:

Authorised

承認日:

2016-06-17

製品の特徴

Health Products Regulatory Authority
05 April 2019
CRN008WV9
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Fasimec Duo 50 mg/ml + 1 mg/ml oral suspension for sheep
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENTS:
Ivermectin
1
mg/ml
Triclabendazole
50
mg/ml
EXCIPIENTS:
Methyl parahydroxybenzoate (E218)
1.4
mg/ml
Propyl parahydroxybenzoate (E216)
0.5
mg/ml
Benzyl alcohol
5.0
mg/ml
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension
Cream coloured aqueous oral suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
For sheep over 3 months of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of mixed trematode (fluke) and nematode or arthropod
infections due to gastrointestinal roundworms, lungworms,
liver fluke and nasal bots.
GASTROINTESTINAL NEMATODES (ADULT AND IMMATURE):
_Haemonchus contortus, Teladorsagia (Ostertagia) circumcincta,
Trichostrongylus spp, Cooperia spp, Nematodirus spp_ including _N._
_battus_, _Strongyloides papillosus, Oesophagostomum spp_, and adult
_Chabertia ovina._
Inhibited larval stages and benzimidazole resistant strains of
_Haemonchus contortus_ and _Teladorsagia (Ostertagia) circumcincta_
are also controlled.
LIVER FLUKE (MATURE, IMMATURE AND EARLY IMMATURE STAGES DOWN TO LESS
THAN 1 WEEK OF AGE):
_Fasciola hepatica_
LUNGWORMS (ADULT AND IMMATURE):
_Dictyocaulus filaria_
NASAL BOTS (ALL STAGES):
_Oestrus ovis_
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
ingredients or any of the excipients.
Health Products Regulatory Authority
05 April 2019
CRN008WV9
Page 2 of 5
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
I. SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and could
ultimately result in ineffective therapy:

Too frequent and repeated use of anthelmintics from the same class,
over an extended